Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.36 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | CTSL | P07711 | 10/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSC | P53634 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11252169 | 0.83 | NPC1 (0.35) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL11321743 | 0.83 | CTSS (0.33) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL13435738 | 0.80 | — | — | |
| SCHEMBL16358078 | 0.77 | CTSS (0.46) | CTSSCTSKCTSLCTSB | |
| SCHEMBL25858713 | 0.77 | CTSS (0.38) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL16372238 | 0.76 | CTSC (0.38) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL8040888 | 0.76 | CTSL (0.41) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL24767283 | 0.75 | POLB (0.37) | POLBKDM4E | |
| SCHEMBL23795558 | 0.74 | CTSB (0.42) | CTSSCTSKCTSLCTSBPOLB | |
| SCHEMBL87370 | 0.72 | CTSS (0.51) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CTSS 4758/4885CTSK 4222/4885CTSL 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.